Legal & General Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-23,498
| Closed | -$2.4M | – | 3426 |
|
|
2023
Q2 | $2.4M | Sell |
23,498
-3,165
| -12% | -$300K | ﹤0.01% | 1837 |
|
|
2023
Q1 | $2.42M | Buy |
26,663
+2,593
| +11% | +$152K | ﹤0.01% | 1795 |
|
|
2022
Q4 | $914K | Sell |
24,070
-1,134
| -4% | -$39K | ﹤0.01% | 2173 |
|
|
2022
Q3 | $634K | Buy |
25,204
+2,062
| +9% | +$57.1K | ﹤0.01% | 2279 |
|
|
2022
Q2 | $703K | Buy |
23,142
+860
| +4% | +$25.7K | ﹤0.01% | 2262 |
|
|
2022
Q1 | $730K | Sell |
22,282
-18
| -0.1% | -$534 | ﹤0.01% | 2300 |
|
|
2021
Q4 | $588K | Buy |
22,300
+47
| +0.2% | +$3.64K | ﹤0.01% | 2364 |
|
|
2021
Q3 | $2.24M | Buy |
22,253
+5,186
| +30% | +$608K | ﹤0.01% | 1972 |
|
|
2021
Q2 | $2.42M | Buy |
17,067
+402
| +2% | +$45.4K | ﹤0.01% | 1883 |
|
|
2021
Q1 | $1.66M | Buy |
16,665
+644
| +4% | +$75.1K | ﹤0.01% | 2052 |
|
|
2020
Q4 | $1.98M | Sell |
16,021
-2,895
| -15% | -$380K | ﹤0.01% | 1899 |
|
|
2020
Q3 | $1.84M | Sell |
18,916
-75
| -0.4% | -$9.37K | ﹤0.01% | 1794 |
|
|
2020
Q2 | $2.96M | Buy |
18,991
+4,937
| +35% | +$751K | ﹤0.01% | 1554 |
|
|
2020
Q1 | $2.03M | Buy |
14,054
+795
| +6% | +$153K | ﹤0.01% | 1578 |
|
|
2019
Q4 | $2.71M | Buy |
13,259
+3,152
| +31% | +$575K | ﹤0.01% | 1648 |
|
|
2019
Q3 | $811K | Buy |
10,107
+6,128
| +154% | +$520K | ﹤0.01% | 2061 |
|
|
2019
Q2 | $376K | Buy |
3,979
+288
| +8% | +$24.9K | ﹤0.01% | 2202 |
|
|
2019
Q1 | $315K | Buy |
3,691
+277
| +8% | +$23K | ﹤0.01% | 2244 |
|
|
2018
Q4 | $192K | Buy |
3,414
+352
| +11% | +$21.5K | ﹤0.01% | 2315 |
|
|
2018
Q3 | $250K | Buy |
3,062
+597
| +24% | +$42.1K | ﹤0.01% | 2291 |
|
|
2018
Q2 | $86K | Buy |
2,465
+497
| +25% | +$15.1K | ﹤0.01% | 2543 |
|
|
2018
Q1 | $40K | Sell |
1,968
-1,107
| -36% | -$28.5K | ﹤0.01% | 2859 |
|
|
2017
Q4 | $86K | Sell |
3,075
-354
| -10% | -$9.88K | ﹤0.01% | 2662 |
|
|
2017
Q3 | $107K | Buy |
3,429
+965
| +39% | +$29K | ﹤0.01% | 2614 |
|
|
2017
Q2 | $78K | Buy |
2,464
+1,501
| +156% | +$36.9K | ﹤0.01% | 2732 |
|
|
2017
Q1 | $22K | Buy |
963
+347
| +56% | +$8.57K | ﹤0.01% | 3058 |
|
|
2016
Q4 | $13K | Buy |
+616
| New | +$15.6K | ﹤0.01% | 3189 |
|
Other funds holding RETA
Legal & General Group's RETA Position: Q3 2023 in Review
Legal & General Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 23,498 shares — an estimated $2.4M sold.
Legal & General Group first reported a position in RETA in Q4 2016 and held it in 27 quarters. The position peaked at $2.96M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Legal & General Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Legal & General Group sold 23,498 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.4M.
- Legal & General Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 27 quarters.
- Legal & General Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.96M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Legal & General Group's 13F filing for Q3 2023, filed 14 Nov 2023.